Bladder transitional cell carcinoma

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …

This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

Researchers are studying eribulin mesylate, a chemotherapy drug, in people with urothelial cancer that has spread or cannot be removed by surgery, and who also have kidney problems. The trial has two parts: one to find the highest dose patients can tolerate, and another to see ho…

This phase 2 trial tests whether giving focused radiation (SBRT) along with immunotherapy drugs (cemiplimab, with or without fianlimab) before bladder removal can safely shrink muscle-invasive bladder tumors. The study enrolls 44 patients who cannot or choose not to take standard…

This study tests a drug called sacituzumab govitecan in people with advanced bladder cancer that has spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the cancer. About 827 adults with good organ function and a life expectancy o…

This Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…

This Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…

This large Phase 3 trial is testing whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy can help people with advanced bladder cancer that cannot be removed by surgery. Over 1,200 participants worldwide are receiving either che…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This early-phase study tested a new drug called UGN-201 in 10 people with bladder cancer who were scheduled to have their bladder removed. The main goal was to check the drug's safety and see if it caused any serious side effects or surgery delays. Researchers also looked for sig…

This early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with non-muscle-invasive bladder cancer. The drug is injected directly into the tumor, sometimes with a laser. The main goal is to see if this approach is safe and feasible. About 55 pa…

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…

This phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and h…

This study tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than standard chemotherapy for people with advanced bladder cancer that has spread (stage IV). Over 1,100 participants received either the drug combination, durvalumab alone, or chemo. The…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from growing after initial chemotherapy. About 654 patients will receive either the combination or avelumab alone as maintenance therapy. The goal is to s…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This study tests an experimental drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced urothelial cancer that has spread. The goal is to see if it works better than standard chemotherapy. About 375 participants will be enrolled, some who have not…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. The goal is to see if the combination helps shrink tumors and allows patie…

This study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot …

This study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…

This early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…

This early-phase trial tests whether adding the blood pressure drug propranolol to standard immunotherapy and chemotherapy can help shrink bladder cancer that has spread to lymph nodes before surgery. The study enrolls 12 patients and primarily checks for safety and side effects.…

This phase II trial tests a combination of two chemotherapy drugs, gemcitabine and cisplatin, in people with muscle-invasive bladder cancer whose tumors have specific DNA repair gene changes (DDR alterations). The goal is to see if these patients can avoid bladder removal surgery…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…

This was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…

This was a small early-stage trial testing a mix of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for people with advanced bladder cancer who had not yet received any treatment. The goal was to see if the combination was safe and could slow cancer growth. However, th…

This pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a mod…

This phase 2 trial is testing a combination of three drugs—sacituzumab govitecan, zimberelimab, and domvanalimab—given before and after surgery for muscle-invasive bladder cancer. The study includes 70 patients who cannot take standard cisplatin chemotherapy. The main goal is to …

This early-stage study is testing a combination of three drugs—sacituzumab tirumotecan, enfortumab vedotin, and pembrolizumab—in people with advanced bladder cancer that has spread or cannot be surgically removed. The trial has two parts: first, to find safe doses of the two-drug…

This phase 2 trial is testing whether adding propranolol, a common blood pressure drug, to standard immunotherapy can help control advanced bladder cancer. The study enrolled 6 adults with urothelial carcinoma that has spread or cannot be removed by surgery. Researchers are prima…

This study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tested a combination of two chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder for people with early-stage bladder cancer who had not received standard BCG therapy. The goal was to see if this treatment could prevent the cancer from coming …

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This phase II trial tests a combination of an immunotherapy drug called sasanlimab and focused radiation given before bladder removal surgery in 33 patients with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this approach is safe, fea…

This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…

Researchers at Fox Chase Cancer Center are testing whether a standardized cystoscopy exam with tissue sampling, done right before radical cystectomy, can reliably predict which bladder tumors have disappeared (pT0). The study enrolls 65 adults with urothelial carcinoma scheduled …

This study is testing a simple urine test called CxBladder to see if it can accurately detect when bladder cancer comes back. Currently, patients need a camera inserted into the bladder (cystoscopy) for monitoring, which is uncomfortable and costly. The study will collect urine s…

This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…

This study is testing a new urine test called Bladder CARE™ to see if it can detect bladder cancer in people whose standard tests (cystoscopy or cytology) gave unclear results. About 80 adults with suspicious but inconclusive findings will provide a urine sample before their rout…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…